Patents Assigned to PATHWAYS NEURO PHARMA, INC.
  • Neuroreceptor compositions and methods of use
    Patent number: 11760788
    Abstract: Compositions and methods for the treatment of neurological disorders whereby vectors contain codon-optimized nucleic acids for expression in humans, encoding a human dopamine receptor D1 protein, a human 5-Hydroxytryptamine receptor 4 protein, and a human G-protein coupled receptor 139).
    Type: Grant
    Filed: March 2, 2021
    Date of Patent: September 19, 2023
    Assignee: Pathways Neuro Pharma, Inc.
    Inventors: Warren C. Lau, Brad Thompson
  • Methods, compositions, and uses of novel FYN kinase inhibitors
    Patent number: 11701353
    Abstract: The present invention provides methods for inhibiting Fyn kinase, using 5-3-pyridin-2-amine, 6-3-imidazo[1,2-a] pyrazine, 6-3-imidazo[1,2-b] pyridazine, N-(5-imidazo [2,1-b][1,3,4] thiadiazol-2-yl)-amine, 4-3-1H-pyrazolo[3,4-b] pyridine, and N-(3-imidazo [1,2-b] pyridazin-6-yl) amine compounds and methods of treatment, prevention, inhibition or amelioration of diseases and conditions associated with Fyn kinase using such compounds.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: July 18, 2023
    Assignee: Pathways Neuro Pharma, Inc.
    Inventor: Warren C. Lau
  • NEURORECEPTOR COMPOSITIONS AND METHODS OF USE
    Publication number: 20220281952
    Abstract: The present disclosure provides compositions and methods for the treatment of neurological disorders.
    Type: Application
    Filed: March 2, 2021
    Publication date: September 8, 2022
    Applicant: Pathways Neuro Pharma, Inc.
    Inventors: Warren C. LAU, Brad THOMPSON
  • Gene Therapy for Addiction Disorders
    Publication number: 20220152222
    Abstract: The present invention encompasses treatments for neurologic disorders with recombinant vims vectors encoding G-protein coupled receptors. In particular, the invention is directed to the treatment of addiction disorders including but not limited to alcohol addiction and opiate addiction.
    Type: Application
    Filed: February 27, 2020
    Publication date: May 19, 2022
    Applicant: PATHWAYS NEURO PHARMA, INC.
    Inventors: Warren C. LAU, Brad THOMPSON